EXELIXIS AND MERCK SIGN CLINICAL DEVELOPMENT COLLABORATION TO EVALUATE INVESTIGATIONAL ZANZALINTINIB IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN HEAD AND NECK CANCER AND IN COMBINATION WITH WELIREG® (BELZUTIFAN) IN RENAL CELL CARCINOMA

Reuters · 10/14 12:00

Please log in to view news